Trials / Completed
CompletedNCT00647764
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Esanex Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNX-5422 Mesylate Hsp90 inhibitor | dose escalated, tablets twice a week; undetermined duration until disease progression |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2008-04-01
- Last updated
- 2012-05-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00647764. Inclusion in this directory is not an endorsement.